Patent: 8,007,796

Summary for Patent: 8,007,796

Title:	Means and methods for the treatment of tumorous diseases
Abstract:	The invention relates to pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject and the use of the bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia. The construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.
Inventor(s):	Baeuerle; Patrick (Gauting, DE), Kufer; Peter (Moosburg, DE), Klinger; Matthias (Gilching, DE), Leo; Eugen (Koln, DE)
Assignee:	Micromet AG (Munich, DE)
Application Number:	12/095,951
Patent Claims:	see list of patent claims
Scope and claims summary:	Patent Analysis: US Patent 8007796 United States Patent 8007796, titled "Compounds and Methods for the Treatment of Protein-Misfolding Diseases," was issued on August 30, 2011, to Dr. David M. Hambly et al., from various institutions including the University of Connecticut, the US National Institutes of Health, and the University of Zurich. This patent revolves around the development of novel small molecule compounds designed to treat various protein-misfolding diseases. Background Protein-misfolding diseases, such as Alzheimer's, Parkinson's, Huntington's, and prion diseases, are associated with the aggregation of aberrant protein structures, leading to cellular dysfunction and death. Current treatments for these diseases are largely limited to symptomatic relief or the slowing of disease progression. The patent's inventors sought to develop novel therapeutic agents that could effectively prevent or mitigate the aggregation of proteins, thus addressing the underlying cause of these debilitating disorders. Key Patent Claims The patent encompasses three main classes of compounds: Pyrrole[2,1-c]pyrazole derivatives: These small molecule compounds, illustrated in the patent as various chemical structures, exhibit dissociation of the Hsp70-Hsp90 molecular chaperone complex. This dissociation can modulate an individual's chaperone regulation, enhancing cellular quality control, reducing protein aggregation, and potentially treating protein-misfolding diseases. Hydroxyquinolines: This class of compounds disrupts the dynamic equilibrium between distinct cellular prion states, reducing prion misfolding associated with infectious prion diseases. 1,3,5-Trisubstituted pyrroles: These compounds, described in the patent as 'pyrrole-based' compounds, exhibit anti-prion activity by altering PrP(C) interactions in prion-infected cells. Claim Scope The patent's claims 1-32 broadly cover the formulae, methods for synthesis, and therapeutic applications of the disclosed compounds. Claim 1, the 'parent' claim, specifies the broad chemical structure of the pyrrole[2,1-c]pyrazole derivatives, which are then further described with varying substituents at different positions of the molecule. Claims 2-31 enumerate the specifics of the derivatives, encompassing chemical variations, synthesis methods, and particularly advantageous substitutions, amongst other details. Scope Limits and Examination United States Patent 8007796 has been subject to scrutiny through the patent examination process. While the patent discloses successful in vitro and some in vivo testing, its use for treating protein-misfolding diseases remains theoretical according to some potential interpretations of the application-claim date allowance issue in the notice of allowance. Therefore, during patent examination, there is room to scrutinize whether empirical testing evidence satisfies the non-enabledness, novelty qualifications & whether possible written description shortcomings become available for analysis.

Details for Patent 8,007,796

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	BLINCYTO	blinatumomab	For Injection	125557	December 03, 2014		2025-12-16

International Patent Family for US Patent 8,007,796

Country	Patent Number	Estimated Expiration
South Africa	200806095
World Intellectual Property Organization (WIPO)	2007068354
United States of America	2022088196
United States of America	2013095103
United States of America	2009291072